On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Technology Set to Benefit as Study Shows More Benefits of Cannabidiol

  • Cannabidiol (CBD) combats anxiety, inflammation, nausea and vomiting
  • Low side-effect profile means high doses of cannabidiol can be used for treatment of schizophrenia, dementia, diabetes and nausea
  • Lower doses promote and maintain health with anti-oxidative, anti-inflammatory and neuroprotective effects
  • Lexaria Bioscience Corp. set to benefit from increasing interest in CBD as patented technology improves taste, rapidity and effectiveness of bioactive compounds including cannabinoids

A new scientific review of the safety and side effects of cannabidiol confirms and expands on the myriad known health benefits of cannabidiol and the compound’s lack of side effects.

The review, titled “An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies,” was published in the journal Cannabis and Cannabinoid Research in June. To view the full publication, visit: http://nnw.fm/cbd-clinical-overview-pdf.

Cannabidiol has a number of beneficial effects, the study states; it is anti-inflammatory, anxiolytic, antiemetic and antipsychotic. This can only increase the demand for cannabidiol (CBD) products and is good news for Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP). Lexaria has patented a revolutionary lipophilic delivery method which allows accurate, timely delivery of cannabinoids without the need for users to smoke, vape or otherwise inhale the substance.

Lexaria out-licenses its proprietary technology for improved taste, increased speed and efficiency in the delivery of bioactive compounds, including cannabinoids. The special manufacturing process infuses CBD within lipids, which form the basis of the human endocannabinoid system. Lexaria Bioscience’s new process masks the undesirable taste of cannabidiol, which eliminates the need for added sugar and results in a healthier product.

The review’s authors, Iffland Kerstin and Grotenhermen Franjo, concluded that along with the beneficial effects, the safety profile of CBD is excellent. Chronic use and high doses of up to 1,500 mg per day have repeatedly shown to be well tolerated. Cannabidiol does not alter physiological parameters such as heart rate and blood pressure and does not adversely affect psychological and psychomotor functions, food intake or gastrointestinal transit.

The study’s authors reviewed clinical data and animal studies to extend and update a comprehensive survey by Bergamaschi et al. in 2011 on CBD safety and side effects; they concluded that CBD has a much better side effect profile than other drugs used for the treatment of epilepsy and psychotic disorders.

Several studies have shown cannabidiol to be effective in the treatment of epilepsy. In one study, CBD treatment reduced seizures by 45% in 261 young children who were not receiving relief from standard medications. In another study, CBD reduced the frequency of seizures by 39% in therapy-resistant epilepsy patients.

Cannabidiol has also been shown to have anti-anxiety effects equivalent to a standard dose of imipramine, a selective serotonin reuptake inhibitor sold as Tofranil and commonly used to treat anxiety and depression.

Studies have found that CBD reduces inflammation in the gastrointestinal system, treats symptoms of multiple sclerosis and helps with the management of glaucoma.

According to the study review, cannabidiol has also been shown to:

  • help with cannabis withdrawal
  • reduce heroin-seeking behaviors
  • reduce psychotic symptoms in Parkinson’s patients
  • reduce the likelihood of developing diabetes
  • positively modulate the immune system in diseases such as multiple sclerosis, arthritis and diabetes
  • reduce amyloid beta neuro-inflammation and prevent the development of a social recognition deficit in Alzheimer’s disease.
  • reduce swelling and inflammation in arthritis
  • prevent or slow the spread of certain types of aggressive cancer cells
  • reduce weight gain
  • reduce symptoms of psychiatric disorders such as psychosis and bipolar disorder

Cannabidiol is not the only substance which can be formulated and delivered via Lexaria’s revolutionary delivery method; the patented technology can be used for delivery of nicotine, vitamins, analgesics and a variety of other substances. Tests by an independent, third-party lab show that Lexaria’s technological process and lipid formulation improve intestinal absorption by as much as 500%.

Patents have been issued to the company in the U.S. and Australia protecting Lexaria’s intellectual property for the edible delivery of all non-psychoactive cannabinoids, including cannabinoid edibles. A variety of food and beverage formats are protected by the patent, including tea, coffee, cocoa powder, fresh foods and meats, dairy products, pastas, breads, seeds, nuts, spices, herbs, candies, flavorings and more.

Lexaria is primarily a B2B enterprise, and it is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the U.S., and abroad.

For more information, visit the company’s website at www.LexariaEnergy.com

More from NetworkNewsWire

Moleculin Biotech, Inc. (NASDAQ: MBRX) is “One to Watch”

ProBility Media Corp.’s (PBYA) E-Learning Brand Is Transforming Businesses

ChineseInvestors.com (CIIX) Takes Aim at North American, Chinese Cannabidiol Markets

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.networknewswire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office


Select A Month

NetworkNewsWire Currently Accepts



Bitcoin Cash

Bitcoin Cash

Doge Coin






USD Coin

USD Coin

Contact us: 212.418.1217